دورية أكاديمية
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
| العنوان: | Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). |
|---|---|
| المؤلفون: | Slimano F; Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com., Baudouin A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr., Zerbit J; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com., Toulemonde-Deldicque A; Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com., Thomas-Schoemann A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com., Chevrier R; Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr., Daouphars M; Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr., Madelaine I; Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr., Pourroy B; Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr., Tournamille JF; Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com., Astier A; Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com., Ranchon F; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr., Cazin JL; Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr., Bardin C; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr., Rioufol C; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr. |
| المصدر: | Cancer treatment reviews [Cancer Treat Rev] 2020 Aug; Vol. 88, pp. 102063. Date of Electronic Publication: 2020 Jun 23. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Amsterdam : Elsevier Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | Coronavirus Infections/*drug therapy , Coronavirus Infections/*immunology , Medical Oncology/*standards , Neoplasms/*drug therapy , Neoplasms/*immunology , Pharmacy/*standards , Pneumonia, Viral/*drug therapy , Pneumonia, Viral/*immunology, Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Betacoronavirus/isolation & purification ; COVID-19 ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Coronavirus Infections/virology ; Humans ; Medical Oncology/methods ; Neoplasms/virology ; Pandemics ; Pharmacy/methods ; Pneumonia, Viral/virology ; Practice Guidelines as Topic ; SARS-CoV-2 |
| مستخلص: | The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2020 Elsevier Ltd. All rights reserved.) |
| References: | Ann Oncol. 2018 Nov 1;29(11):2208-2213. (PMID: 30215677) Biol Blood Marrow Transplant. 2005 Oct;11(10):781-96. (PMID: 16182179) Int J Cardiol. 2016 Dec 1;224:366-375. (PMID: 27673693) Lancet Oncol. 2016 Mar;17(3):299-308. (PMID: 26858122) Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151) Lancet Oncol. 2018 Jul;19(7):953-964. (PMID: 29866475) Neuro Oncol. 2020 Apr 11;:. (PMID: 32277236) Clin Infect Dis. 2009 Mar 15;48(6):772-86. (PMID: 19207081) JCO Oncol Pract. 2020 Sep;16(9):579-586. (PMID: 32453656) J Clin Oncol. 2012 May 10;30(14):1692-8. (PMID: 22473169) Bull Cancer. 2020 Apr;107(4):400-402. (PMID: 32229048) J Am Coll Clin Pharm. 2020 Jun;3(4):829. (PMID: 32838217) Pharmacol Res. 2020 Jun;156:104776. (PMID: 32251726) Stem Cells Transl Med. 2019 May;8(5):441-449. (PMID: 30735000) BMJ. 2020 Mar 27;368:m1185. (PMID: 32220865) Lancet Oncol. 2011 Dec;12(13):1249-57. (PMID: 21741307) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570) Prog Urol. 2020 Apr;30(5):221-231. (PMID: 32224294) PLoS Med. 2006 Sep;3(9):e343. (PMID: 16968120) J Med Virol. 2020 Oct;92(10):1875-1883. (PMID: 32441789) Lancet Oncol. 2020 Apr;21(4):e181. (PMID: 32142621) Eur J Cancer. 2020 May;131:68-75. (PMID: 32305010) Breast Cancer Res Treat. 2016 Nov;160(1):17-28. (PMID: 27632288) Ann Oncol. 2020 Aug;31(8):1040-1045. (PMID: 32387456) Lancet Oncol. 2009 Jun;10(6):589-97. (PMID: 19482247) Lancet. 2020 May 16;395(10236):1569-1578. (PMID: 32423584) Lancet Oncol. 2020 May;21(5):619-621. (PMID: 32220659) Ann Oncol. 2020 May;31(5):553-555. (PMID: 32201224) Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. (PMID: 31219357) Bone Marrow Transplant. 2020 Nov;55(11):2071-2076. (PMID: 32404975) Ann Intern Med. 2020 Jun 2;172(11):756-758. (PMID: 32219410) Cancer. 2012 Sep 15;118(18):4627-33. (PMID: 22359314) J Clin Oncol. 2018 May 20;36(15):1469-1477. (PMID: 29620995) J Allergy Clin Immunol Pract. 2020 May;8(5):1489-1491. (PMID: 32220575) JAMA Oncol. 2020 Jul 1;6(7):1108-1110. (PMID: 32211820) Nat Rev Clin Oncol. 2020 May;17(5):268-270. (PMID: 32242095) JAMA. 2011 Jun 8;305(22):2335-42. (PMID: 21642686) Crit Rev Oncol Hematol. 2015 May;94(2):189-200. (PMID: 25638703) Leukemia. 2019 Jul;33(7):1736-1746. (PMID: 30696949) Br J Surg. 2020 Jun;107(7):785-787. (PMID: 32191340) Cancer Discov. 2020 Jul;10(7):935-941. (PMID: 32357994) Br J Clin Pharmacol. 2000 Jun;49(6):549-54. (PMID: 10848718) Respir Med Res. 2020 Nov;78:100769. (PMID: 32563968) Nat Med. 2020 May;26(5):665-671. (PMID: 32405058) Ann Oncol. 2020 Jul;31(7):961-964. (PMID: 32247642) ESMO Open. 2020 Jun;5(Suppl 3):. (PMID: 32581069) BMJ. 2020 Mar 25;368:m1174. (PMID: 32213482) J Visc Surg. 2020 Jun;157(3S1):S7-S12. (PMID: 32249098) Clin Infect Dis. 2004 Nov 1;39(9):1300-6. (PMID: 15494906) Cancer Discov. 2020 Aug;10(8):1121-1128. (PMID: 32398243) Bull Cancer. 2020 May;107(5):528-537. (PMID: 32278467) Breast Cancer Res Treat. 2013 Jun;139(3):923-9. (PMID: 23760858) JCO Oncol Pract. 2020 Nov;16(11):e1282-e1290. (PMID: 32539650) Clin Pharmacol Ther. 2010 Feb;87(2):166-74. (PMID: 20010556) Infect Dis (Lond). 2019 Jul;51(7):502-509. (PMID: 31081422) Drug Saf. 2016 Nov;39(11):1073-1091. (PMID: 27534751) Int J Gynecol Cancer. 2020 May;30(5):561-563. (PMID: 32221023) Res Social Adm Pharm. 2021 Jan;17(1):1813-1818. (PMID: 32278766) Pancreas. 2013 Nov;42(8):1311-5. (PMID: 24152956) Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541) JAMA. 2020 May 12;323(18):1775-1776. (PMID: 32203977) Lancet Oncol. 2020 May;21(5):629-630. (PMID: 32247319) Res Social Adm Pharm. 2021 Jan;17(1):2053. (PMID: 32273254) Immunotherapy. 2020 Apr;12(5):269-273. (PMID: 32212881) Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983. (PMID: 29388675) Lung Cancer. 2019 Sep;135:196-204. (PMID: 31446995) Bull Cancer. 2020 Apr;107(4):395-397. (PMID: 32245603) Ann Oncol. 2016 Jun;27(6):998-1005. (PMID: 26951625) Ann Surg. 2016 Aug;264(2):370-7. (PMID: 26445474) Lancet Oncol. 2020 May;21(5):624-627. (PMID: 32277907) JAMA Cardiol. 2020 Jul 1;5(7):831-840. (PMID: 32219363) Lung Cancer Manag. 2020 Jan 16;8(4):LMT18. (PMID: 31983926) Eur Respir J. 2020 May 14;55(5):. (PMID: 32217650) Support Care Cancer. 2020 Aug;28(8):3557-3569. (PMID: 32189099) N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490) J Thorac Oncol. 2020 Jul;15(7):1119-1136. (PMID: 32422364) Dig Liver Dis. 2020 Jun;52(6):597-603. (PMID: 32418773) Integr Cancer Ther. 2020 Jan-Dec;19:1534735420912811. (PMID: 32178547) N Engl J Med. 2020 Jun 11;382(24):2327-2336. (PMID: 32275812) Br J Clin Pharmacol. 2019 Oct;85(10):2280-2291. (PMID: 30907446) Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. (PMID: 32424196) ESMO Open. 2020 May;5(Suppl 3):. (PMID: 32457036) Cancer Immunol Res. 2018 Sep;6(9):1093-1099. (PMID: 29991499) Lancet. 2019 May 11;393(10184):1948-1957. (PMID: 30982686) J Am Geriatr Soc. 2014 Aug;62(8):1505-12. (PMID: 25041361) Acta Haematol. 2020;143(5):410-416. (PMID: 32305989) ESMO Open. 2020 May;5(Suppl 3):. (PMID: 32439716) Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) |
| فهرسة مساهمة: | Keywords: COVID-19; Clinical trials; Drug safety; Drug-drug interactions; Drug-related problems; Herb-Drug interactions; Immune depression |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20200706 Date Completed: 20200729 Latest Revision: 20240329 |
| رمز التحديث: | 20240329 |
| مُعرف محوري في PubMed: | PMC7308737 |
| DOI: | 10.1016/j.ctrv.2020.102063 |
| PMID: | 32623296 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-1967 |
|---|---|
| DOI: | 10.1016/j.ctrv.2020.102063 |